In this study, we developed an inhalable Nano–in–Micro (NiM) system for localized delivery of Sorafenib (Sor) in non-small cell lung cancer (NSCLC) therapy. Sor was encapsulated into mucus-penetrating and folate-targeted polymeric nanoparticles (FA-PPP-NPs@Sor), produced starting from the α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA), functionalised with poly(lactic-co-glycolic acid) (PLGA), and folate-conjugated polyethylene glycol (PEG-FA) FA (DDPLGA = 3.3 mol %, DDPEG–FA ≈ 8 chains/molecule). Nanoprecipitation produced 109 nm particles, easy to redisperse, with a DL of 10 wt%, which showed a controlled release of the drug, about 8.4 wt% (pH 7.4) vs. 21.7 wt% (pH 5.5) in 24 h. A selective cytotoxicity towards A549 lung cancer cells via folate receptor-mediated internalization was found, being IC50 = 18 ± 3.2 μM, significantly lower than those found both in 16HBE cells (IC50 = 69 ± 3.1 μM and free Sor (IC50 = 17.7 ± 2.3 μM). The receptor involvement was confirmed by competitive folate blocking, which raised IC50 >100 μM. Wound healing assay performed to evaluate the ability of Sor-loaded nanoparticles to inhibit or reduce cell migration showed 27 % vs. 40 % wound closure at 48 h (NiM vs Sor). The nanoparticles were further incorporated into inhalable microparticles via spray drying (SD), using mannitol, leucine, N-acetylcysteine, and ammonium bicarbonate as functional excipients (yield 63 wt%, EE = 100 wt%, DL = 0.35 wt%). The spray dried NiMSor microparticles exhibited a MMAD and a FPF, respectively, of 2.2 μm and 76 %, suitable for deep lung delivery. Furthermore, their storage at r.t. and dissolution in water reconstitutes the nanoparticle dispersion. Rheology tests demonstrated time– and concentration– dependent mucus thinning. Overall, this study presents a promising inhalable platform for targeted lung cancer therapy, combining targeted cytotoxicity, mucus penetration, controlled release, and favourable aerosol properties.

Scialabba, C., Corsaro, F., Drago, S.E., Craparo, E.F., Cavallaro, G. (2025). Exploring a mucoacting spray-dried nanoparticle-in-microparticle inhalable formulation for targeted pulmonary delivery of sorafenib in lung cancer therapy. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 685, 126290 [10.1016/j.ijpharm.2025.126290].

Exploring a mucoacting spray-dried nanoparticle-in-microparticle inhalable formulation for targeted pulmonary delivery of sorafenib in lung cancer therapy

Scialabba, Cinzia;Corsaro, Federico;Drago, Salvatore Emanuele;Craparo, Emanuela Fabiola
;
Cavallaro, Gennara
2025-01-01

Abstract

In this study, we developed an inhalable Nano–in–Micro (NiM) system for localized delivery of Sorafenib (Sor) in non-small cell lung cancer (NSCLC) therapy. Sor was encapsulated into mucus-penetrating and folate-targeted polymeric nanoparticles (FA-PPP-NPs@Sor), produced starting from the α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA), functionalised with poly(lactic-co-glycolic acid) (PLGA), and folate-conjugated polyethylene glycol (PEG-FA) FA (DDPLGA = 3.3 mol %, DDPEG–FA ≈ 8 chains/molecule). Nanoprecipitation produced 109 nm particles, easy to redisperse, with a DL of 10 wt%, which showed a controlled release of the drug, about 8.4 wt% (pH 7.4) vs. 21.7 wt% (pH 5.5) in 24 h. A selective cytotoxicity towards A549 lung cancer cells via folate receptor-mediated internalization was found, being IC50 = 18 ± 3.2 μM, significantly lower than those found both in 16HBE cells (IC50 = 69 ± 3.1 μM and free Sor (IC50 = 17.7 ± 2.3 μM). The receptor involvement was confirmed by competitive folate blocking, which raised IC50 >100 μM. Wound healing assay performed to evaluate the ability of Sor-loaded nanoparticles to inhibit or reduce cell migration showed 27 % vs. 40 % wound closure at 48 h (NiM vs Sor). The nanoparticles were further incorporated into inhalable microparticles via spray drying (SD), using mannitol, leucine, N-acetylcysteine, and ammonium bicarbonate as functional excipients (yield 63 wt%, EE = 100 wt%, DL = 0.35 wt%). The spray dried NiMSor microparticles exhibited a MMAD and a FPF, respectively, of 2.2 μm and 76 %, suitable for deep lung delivery. Furthermore, their storage at r.t. and dissolution in water reconstitutes the nanoparticle dispersion. Rheology tests demonstrated time– and concentration– dependent mucus thinning. Overall, this study presents a promising inhalable platform for targeted lung cancer therapy, combining targeted cytotoxicity, mucus penetration, controlled release, and favourable aerosol properties.
2025
Settore CHEM-08/A - Tecnologia, socioeconomia e normativa dei medicinali e dei prodotti per il benessere e per la salute
Scialabba, C., Corsaro, F., Drago, S.E., Craparo, E.F., Cavallaro, G. (2025). Exploring a mucoacting spray-dried nanoparticle-in-microparticle inhalable formulation for targeted pulmonary delivery of sorafenib in lung cancer therapy. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 685, 126290 [10.1016/j.ijpharm.2025.126290].
File in questo prodotto:
File Dimensione Formato  
pubbl88_IntJPham2025.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 7.88 MB
Formato Adobe PDF
7.88 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/692311
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact